A phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancer

Oncology Reports

Volumn 27, Issue 3, 2012, Pages 657-663

  Trinh, X B ^a,b   Sas, L ^a   Van Laere, S J ^a   Prove A ^a   Deleu, I ^a   Rasschaert, M ^a   Van De Velde, H ^c   Vinken, P ^c   Vermeulen, P B ^a   Van Dam, P A ^a   Wojtasik, A ^a   De Mesmaeker, P ^a   Tjalma, W A ^b   Dirix, L Y ^a  

^a SINT AUGUSTINUS HOSPITAL   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Bortezomib; Endocrine resistance; Estrogen receptor; Metastatic breast cancer; NF B; Proteasome inhibitor

Indexed keywords

AROMATASE INHIBITOR; BORTEZOMIB; INTERLEUKIN 6; INTERLEUKIN 8; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; VASCULOTROPIN A;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER TISSUE; CLINICAL ARTICLE; CONJUNCTIVITIS; DIARRHEA; DOWN REGULATION; DRUG RESPONSE; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME INHIBITION; FATIGUE; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGIC DISEASE; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT FAILURE; VOMITING;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BORONIC ACIDS; BREAST NEOPLASMS; CYTOKINES; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; MIDDLE AGED; NF-KAPPA B; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; SIGNAL TRANSDUCTION; TAMOXIFEN;

EID: 84856283124     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1562     Document Type: Article

References (48)

1. Veronesi U, Boyle P, Goldhirsch A, Orecchia R and Viale G: Breast cancer. Lancet 365: 1727-1741, 2005. (Pubitemid 40719108)
2. Arpino G, Green SJ, Allred DC, Lew D, Martino S, Osborne CK and Elledge RM: HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res 10: 5670-5676, 2004. (Pubitemid 39180941)
3. Atalay G, Cardoso F, Awada A and Piccart MJ: Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer. Ann Oncol 14: 1346-1363, 2003. (Pubitemid 37185280)
4. Osborne CK, Shou J, Massarweh S and Schiff R: Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 11: S865-S870, 2005.
5. Herynk MH and Fuqua SAW: Estrogen receptor mutations in human disease. Endocr Rev 25: 869-898, 2004. (Pubitemid 39657771)
6. Johnston SR: New strategies in estrogen receptor-positive breast cancer. Clin Cancer Res 16: 1979-1987, 2010.
7. Biswas DK, Cruz AP, Gansberger E and Pardee AB: Epidermal growth factor-induced nuclear factor kappa B activation: a major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc Natl Acad Sci USA 97: 8542-8547, 2000. (Pubitemid 30639709)
8. Biswas DK, Dai SC, Cruz A, Weiser B, Graner E and Pardee AB: The nuclear factor kappa B (NF-kappa B): a potential therapeutic target for estrogen receptor negative breast cancers. Proc Natl Acad Sci USA 98: 10386-10391, 2001. (Pubitemid 32803029)
9. Biswas DK, Shi Q, Baily S, Strickland I, Ghosh S, Pardee AB and Iglehart JD: NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci USA 101: 10137-10142, 2004. (Pubitemid 38891208)
10. Chadwick CC, Chippari S, Matelan E, Borges-Marcucci L, Eckert AM, Keith JC, Albert LM, Leathurby Y, Harris HA, Bhat RA, Ashwell M, Trybulski E, Winneker RC, Adelman SJ, Steffan RJ and Harnish DC: Identification of pathway-selective estrogen receptor ligands that inhibit NF-kappaB transcriptional activity. Proc Natl Acad Sci USA 102: 2543-2548, 2005. (Pubitemid 40279413)
11. Ghisletti S, Meda C, Maggi A and Vegeto E: 17beta-estradiol inhibits inflammatory gene expression by controlling NF-kappaB intracellular localization. Mol Cell Biol 25: 2957-2968, 2005. (Pubitemid 40464301)
12. Liu H, Liu K and Bodenner DL: Estrogen receptor inhibits interleukin- 6 gene expression by disruption of nuclear factor kappaB transactivation. Cytokine 31: 251-257, 2005. (Pubitemid 41097360)
13. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ and Sledge GW: Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 17: 3629-3639, 1997. (Pubitemid 27281838)
14. Pratt MAC, Bishop TE, White D, Yasvinski G, Ménard M, Niu MY and Clarke R: Estrogen withdrawal-induced NF-kappaB activity and bcl-3 expression in breast cancer cells: roles in growth and hormone independence. Mol Cell Biol 23: 6887-6900, 2003. (Pubitemid 37220039)
15. Van Laere SJ, Van der Auwera I, Van den Eynden GG, Elst HJ, Weyler J, Harris AL, van Dam P, Van Marck EA, Vermeulen PB and Dirix LY: Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding. Clin Cancer Res 12: 3249-3256, 2006.
16. Van Laere SJ, Van der Auwera I, Van den Eynden GG, van Dam P, Van Marck EA, Vermeulen PB and Dirix LY: NF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation. Br J Cancer 97: 659-669, 2007. (Pubitemid 47339884)
17. Zhou Y, Eppenberger-Castori S, Marx C, Yau C, Scott GK, Eppenberger U and Benz CC: Activation of nuclear factor-kappaB (NFkappaB) identifies a high-risk subset of hormone-dependent breast cancers. Int J Biochem Cell Biol 37: 1130-1144, 2005. (Pubitemid 40311751)
18. Dunleavy K, Pittaluga S, Czuczman MS, Dave SS, Wright G, Grant N, Shovlin M, Jaffe ES, Janik JE, Staudt LM and Wilson WH: Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 113: 6069-6076, 2009.
19. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A, Palombella V, Adams J and Anderson KC: NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 277: 16639-16647, 2002. (Pubitemid 34967682)
20. Lam LT, Wright G, Davis RE, Lenz G, Farinha P, Dang L, Chan JW, Rosenwald A, Gascoyne RD and Staudt LM: Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-κB pathways in subtypes of diffuse large B-cell lymphoma. Blood 111: 3701-3713, 2008.
21. Palombella VJ, Rando OJ, Goldberg AL and Maniatis T: The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 78: 773-785, 1994. (Pubitemid 24294453)
22. deGraffenried LA, Chandrasekar B, Friedrichs WE, Donzis E, Silva J, Hidalgo M, Freeman JW and Weiss GR: NF-kappa B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen. Ann Oncol 15: 885-890, 2004. (Pubitemid 39004343)
23. Adams J: The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5: 417-421, 2004.
24. Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, Adams J, Esseltine DL, Elliott PJ, Pien CS, Guerciolini R, Anderson JK, Depcik-Smith ND, Bhagat R, Lehman MJ, Novick SC, O'Connor OA and Soignet SL: Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20: 4420-4427, 2002. (Pubitemid 35334752)
25. Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C and Logothetis CJ: Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 22: 2108-2121, 2004. (Pubitemid 41095144)
26. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP and Anderson KC: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348: 2609-2617, 2003. (Pubitemid 36741588)
27. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Bladé J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC and Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352: 2487-2498, 2005.
28. San-Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG and VISTA Trial Investigators: Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359: 906-917, 2008.
29. de Vos S, Goy A, Dakhil SR, Saleh MN, McLaughlin P, Belt R, Flowers CR, Knapp M, Hart L, Patel-Donnelly D, Glenn M, Gregory SA, Holladay C, Zhang T and Boral AL: Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. J Clin Oncol 27: 5023-5030, 2009.
30. Reece DE, Sanchorawala V, Hegenbart U, Merlini G, Palladini G, Fermand JP, Vescio RA, Liu X, Elsayed YA, Cakana A, Comenzo RL and VELCADE CAN2007 Study Group: Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood 114: 1489-1497, 2009.
31. Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl Bancroft C, Sausville E, Adams J, Elliott P and Van Waes C: Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 7: 1419-1428, 2001. (Pubitemid 32708698)
32. Yang CH, Gonzalez-Angulo AM, Reuben JM, Booser DJ, Pusztai L, Krishnamurthy S, Esseltine D, Stec J, Broglio KR, Islam R, Hortobagyi GN and Cristofanilli M: Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. Ann Oncol 17: 813-817, 2006.
33. Engel RH, Brown JA, Von Roenn JH, O'Regan RM, Bergan R, Badve S, Rademaker A and Gradishar WJ: A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience. Cancer Invest 25: 733-737, 2007. (Pubitemid 350223168)
34. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G and A'Hern R: Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer. Clin Cancer Res 12: S1024-S1030, 2006.
35. Papandreou CN and Logothetis CJ: Bortezomib as a potential treatment for prostate cancer. Cancer Res 64: 5036-5043, 2004. (Pubitemid 39006513)
36. Coiffier B, Osmanov EA, Hong X, Scheliga A, Mayer J, Offner F, Rule S, Teixeira A, Walewski J, de Vos S, Crump M, Shpilberg O, Esseltine DL, Zhu E, Enny C, Theocharous P, van de Velde H, Elsayed YA, Zinzani PL and the LYM-3001 study investigators: Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. Lancet Oncol 12: 773-784, 2011.
37. Venkatakrishnan K, Ramanathan R, Sarantopoulos J, Mulkerin D, Shibata S, Hamilton A, Dowlati A, Mani S, Rudek MA, Ivy P, Takimoto CH, Neuwirth R, Parasuraman S and Lorusso PM: Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: results of the phase 1 National Cancer Institute Organ Dysfunction Working Group Study NCI 6432. Blood (ASH Annual Meeting abstracts) 116: 3975, 2010.
38. Brauch H, Murter T and Eichelbaum M: Pharmacogenomics of tamoxifen therapy. Clin Chem 55: 1770-1782, 2009
39. Desta Z, Ward BA, Soukhova NV and Flockhart DA: Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 310: 1062-1075, 2004. (Pubitemid 39108928)
40. Kamdem LK, Flockhart DA and Desta Z: In vitro cytochrome P450-mediated metabolism of exemestane. Drug Metab Dispos 39: 98-105, 2011.
41. Murai K, Yamazaki H, Nakagawa K, Kawai R and Kamataki T: Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes. Xenobiotica 39: 795-802, 2009.
42. Uttamsingh V, Lu C, Miwa G and Gan LS: Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib. Drug Metab Dispos 33: 1723-1728, 2005. (Pubitemid 41539972)
43. Nakanishi C and Toi M: Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 5: 297-309, 2005. (Pubitemid 40488635)
44. Chen L and Madura K: Increased proteasome activity, ubiquitin-conjugating enzymes, and eEF1A translation factor detected in breast cancer tissue. Cancer Res 65: 5599-5606, 2005. (Pubitemid 40911160)
45. Williamson MJ, Silva MD, Terkelsen J, Robertson R, Yu L, Xia C, Hatsis P, Bannerman B, Babcock T, Cao Y and Kupperman E: The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models. Mol Cancer Ther 8: 3234-3243, 2009.
46. Hamilton AL, Eder JP, Pavlick AC, Clark JW, Liebes L, Garcia-Carbonero R, Chachoua A, Ryan DP, Soma V, Farrell K, Kinchla N, Boyden J, Yee H, Zeleniuch-Jacquotte A, Wright J, Elliott P, Adams J and Muggia FM: Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. J Clin Oncol 23: 6107-6116, 2005.
47. Van Waes C, Chang AA, Lebowitz PF, Druzgal CH, Chen Z, Elsayed YA, Sunwoo JB, Rudy SF, Morris JC, Mitchell JB, Camphausen K, Gius D, Adams J, Sausville EA and Conley BA: Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 63: 1400-1412, 2005. (Pubitemid 41628035)
48. Märten A, Zeiss N, Serba S, Mehrle S, von Lilienfeld-Toal M and Schmidt J: Bortezomib is ineffective in an orthotopic mouse model of pancreatic adenocarcinoma. Mol Cancer Ther 7: 3624-3631, 2008.